Cyclo Therapeutics Stock Alpha and Beta Analysis
| CYTH Stock | USD 0.70 0.03 4.48% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cyclo Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cyclo Therapeutics over a specified time horizon. Remember, high Cyclo Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cyclo Therapeutics' market risk premium analysis include:
Beta (0.64) | Alpha 0.46 | Risk 9.18 | Sharpe Ratio 0.0731 | Expected Return 0.67 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cyclo |
Cyclo Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cyclo Therapeutics market risk premium is the additional return an investor will receive from holding Cyclo Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cyclo Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cyclo Therapeutics' performance over market.| α | 0.46 | β | -0.64 |
Cyclo Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cyclo Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Cyclo Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cyclo Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Cyclo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cyclo Therapeutics shares will generate the highest return on investment. By understating and applying Cyclo Therapeutics stock market price indicators, traders can identify Cyclo Therapeutics position entry and exit signals to maximize returns.
Cyclo Therapeutics Return and Market Media
The median price of Cyclo Therapeutics for the period between Sat, Dec 14, 2024 and Fri, Mar 14, 2025 is 0.74 with a coefficient of variation of 17.42. The daily time series for the period is distributed with a sample standard deviation of 0.13, arithmetic mean of 0.74, and mean deviation of 0.1. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Cyclo Therapeutics, Inc. announced that it has received 1 million in funding - Marketscreener.com | 01/06/2025 |
2 | Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium 2025 | 01/14/2025 |
3 | Acquisition by Fine N Scott of 299402 shares of Cyclo Therapeutics at 0.71 subject to Rule 16b-3 | 01/29/2025 |
4 | Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC Open-Label Sub-Study in Patients | 02/07/2025 |
5 | 3 Penny Stocks to Watch Now, 21125 - TipRanks | 02/10/2025 |
6 | Acquisition by Shanahan William S of 25140 shares of Cyclo Therapeutics subject to Rule 16b-3 | 02/27/2025 |
7 | Acquisition by Strattan Ce Rick of 8089 shares of Cyclo Therapeutics subject to Rule 16b-3 | 03/03/2025 |
8 | Disposition of 2514970 shares by Rafael Holdings, Inc. of Cyclo Therapeutics at 0.71 subject to Rule 16b-3 | 03/05/2025 |
9 | Cyclo Therapeutics secures 2.5 million in funding - Investing.com India | 03/06/2025 |
10 | Acquisition by Ostronic Francis Patrick of 65869 shares of Cyclo Therapeutics at 0.95 subject to Rule 16b-3 | 03/07/2025 |
11 | Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results | 03/13/2025 |
About Cyclo Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cyclo or other stocks. Alpha measures the amount that position in Cyclo Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 14.59 | 41.5 | 37.35 | 31.08 | PTB Ratio | 16.31 | 5.46 | 4.91 | 7.66 |
Cyclo Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cyclo Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyclo Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cyclo Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cyclo Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cyclo Therapeutics' management manipulating its earnings.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Cyclo Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cyclo Therapeutics Backtesting, Cyclo Therapeutics Valuation, Cyclo Therapeutics Correlation, Cyclo Therapeutics Hype Analysis, Cyclo Therapeutics Volatility, Cyclo Therapeutics History and analyze Cyclo Therapeutics Performance. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Cyclo Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.